MCID: GST047
MIFTS: 36

Gastrointestinal Neuroendocrine Tumor

Categories: Cancer diseases, Gastrointestinal diseases, Neuronal diseases

Aliases & Classifications for Gastrointestinal Neuroendocrine Tumor

MalaCards integrated aliases for Gastrointestinal Neuroendocrine Tumor:

Name: Gastrointestinal Neuroendocrine Tumor 12 15
Malignant Gastrointestinal Neuroendocrine Tumour 12
Malignant Gastrointestinal Neuroendocrine Tumor 12
Digestive System Neuroendocrine Neoplasm 70
Gastrointestinal Neuroendocrine Tumour 12
Digestive System Neuroendocrine Tumor 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0050626
UMLS 70 C1333799 C2987127

Summaries for Gastrointestinal Neuroendocrine Tumor

Disease Ontology : 12 A gastrointestinal system cancer that has material basis in neuroendocrine cells.

MalaCards based summary : Gastrointestinal Neuroendocrine Tumor, also known as malignant gastrointestinal neuroendocrine tumour, is related to hyperparathyroidism and carcinoid syndrome. An important gene associated with Gastrointestinal Neuroendocrine Tumor is SST (Somatostatin), and among its related pathways/superpathways are Signaling by GPCR and cAMP signaling pathway. The drugs Everolimus and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and pancreas, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Gastrointestinal Neuroendocrine Tumor

Diseases in the Gastrointestinal Neuroendocrine Tumor family:

Gastrointestinal Neuroendocrine Benign Tumor

Diseases related to Gastrointestinal Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 256)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 29.9 MEN1 GAST CHGA
2 carcinoid syndrome 29.6 SYP SST MEN1 ENO2 CHGA
3 paraganglioma 29.4 SYP SST MEN1 ENO2 CHGA
4 neuroendocrine tumor 29.3 SYP SSTR2 SST MTOR MEN1 GAST
5 neuroendocrine carcinoma 29.1 SYP SST MEN1 GAST ENO2 CHGA
6 hemangioma 28.8 SYP MTOR MEN1 GAST ENO2 CHGA
7 ectopic cushing syndrome 10.3 SST CHGA
8 primary hepatic neuroendocrine carcinoma 10.3 SYP CHGA
9 esophageal neuroendocrine tumor 10.3 SYP CHGA
10 acinar cell cystadenocarcinoma 10.3 SYP CHGA
11 vulvar eccrine porocarcinoma 10.3 SYP CHGA
12 pancreatic serous cystadenocarcinoma 10.3 SYP CHGA
13 vaginal tubulovillous adenoma 10.3 SYP CHGA
14 laryngeal small cell carcinoma 10.3 SYP CHGA
15 papillary thymic adenocarcinoma 10.3 SYP CHGA
16 breast papillary carcinoma 10.3 SYP CHGA
17 esophageal adenoid cystic carcinoma 10.3 SYP CHGA
18 appendix adenocarcinoma 10.3 SYP CHGA
19 pituitary infarct 10.3 SST MEN1
20 glomangiomatosis 10.3 SYP CHGA
21 pulmonary large cell neuroendocrine carcinoma 10.3 SYP CHGA
22 vaginal adenoma 10.3 SYP CHGA
23 type c thymoma 10.3 SSTR2 SST
24 papillary ependymoma 10.3 SYP MEN1
25 autoimmune atrophic gastritis 10.3 GAST CHGA
26 small intestine neuroendocrine neoplasm 10.3 SST MEN1
27 vaginal benign neoplasm 10.3 SYP CHGA
28 chordoid meningioma 10.3 SYP CHGA
29 pancreatic acinar cell adenocarcinoma 10.3 SYP CHGA
30 tanycytic ependymoma 10.3 SYP MEN1
31 extra-adrenal pheochromocytoma 10.3 SYP CHGA
32 peritoneal serous adenocarcinoma 10.3 SYP CHGA
33 postgastrectomy syndrome 10.2 SST GAST
34 gastric antral vascular ectasia 10.2 SST GAST
35 clear cell meningioma 10.2 SYP CHGA
36 pituitary apoplexy 10.2 SST MEN1
37 tsh producing pituitary tumor 10.2 SSTR5 SST
38 diamond-blackfan anemia 5 10.2 SYP SST
39 duodenal benign neoplasm 10.2 SYP SST CHGA
40 laryngeal neuroendocrine tumor 10.2 SYP SST CHGA
41 pituitary adenoma 1, multiple types 10.2 SST MEN1
42 binswanger's disease 10.2 SYP SST CHGA
43 duodenogastric reflux 10.2 SST GAST
44 nasal cavity adenocarcinoma 10.2 SYP GAST
45 meckel diverticulum 10.2 SYP SST CHGA
46 adrenal medulla cancer 10.2 SYP SST CHGA
47 pancreatoblastoma 10.2 SYP SST CHGA
48 cellular ependymoma 10.2 SYP MEN1
49 pulmonary blastoma 10.2 SYP SST CHGA
50 functional gastric disease 10.2 SST GAST

Graphical network of the top 20 diseases related to Gastrointestinal Neuroendocrine Tumor:



Diseases related to Gastrointestinal Neuroendocrine Tumor

Symptoms & Phenotypes for Gastrointestinal Neuroendocrine Tumor

GenomeRNAi Phenotypes related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.36 MTOR
2 Decreased viability GR00055-A-2 9.36 MTOR
3 Decreased viability GR00221-A-1 9.36 MTOR
4 Decreased viability GR00221-A-4 9.36 MTOR
5 Decreased viability GR00231-A 9.36 PKN3
6 Decreased viability GR00240-S-1 9.36 PKN3
7 Decreased viability GR00301-A 9.36 PKN3
8 Decreased viability GR00342-S-1 9.36 MTOR
9 Decreased viability GR00342-S-2 9.36 MTOR PKN3
10 Decreased viability GR00402-S-2 9.36 PKN3

MGI Mouse Phenotypes related to Gastrointestinal Neuroendocrine Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.81 CDKN1A ENO2 MTOR PKN3 SST SSTR1
2 homeostasis/metabolism MP:0005376 9.65 CDKN1A CHGA GAST MEN1 MTOR PKN3
3 nervous system MP:0003631 9.28 CDKN1A CHGA ENO2 MEN1 MTOR SST

Drugs & Therapeutics for Gastrointestinal Neuroendocrine Tumor

Drugs for Gastrointestinal Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
2
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
3
Octreotide Approved, Investigational Phase 2 83150-76-9 6400441 383414
4
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
5
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
6
lanreotide Approved Phase 2 108736-35-2
7
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
8
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
9
Etoposide Approved Phase 2 33419-42-0 36462
10
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
11 Gastrointestinal Agents Phase 2
12 Immunosuppressive Agents Phase 2
13 Immunologic Factors Phase 2
14 Antineoplastic Agents, Hormonal Phase 2
15 Angiogenesis Inhibitors Phase 2
16 Protein Kinase Inhibitors Phase 2
17 Angiopeptin Phase 2
18 Liver Extracts Phase 2
19 topoisomerase I inhibitors Phase 2
20 Etoposide phosphate Phase 2
21
Pancrelipase Approved, Investigational 53608-75-6
22
Resveratrol Investigational 501-36-0 445154
23 Analgesics, Non-Narcotic
24 Analgesics
25 Antirheumatic Agents
26 Antioxidants
27 Anti-Inflammatory Agents
28 Anti-Inflammatory Agents, Non-Steroidal
29 Platelet Aggregation Inhibitors
30 Protective Agents
31 Cola
32 pancreatin

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed NCT02420691 Phase 2 Ribociclib
2 A Phase II Study on Everolimus, an mTOR Inhibitor (Oral Formulation), With Octreotide LAR® in Adult Patients With Advanced, Non-functioning, Well-differentiated Gastrointestinal Neuroendocrine Tumours (GI NET) Completed NCT01567488 Phase 2 Everolimus;octreotide LAR
3 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors Completed NCT00434109 Phase 2 Sunitinib malate
4 A Phase 2 Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) Recruiting NCT03891784 Phase 2 Abemaciclib
5 Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors Recruiting NCT02185443 Phase 2
6 A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®) Active, not recruiting NCT02859064 Phase 2 Lanreotide
7 Phase II Trial of Etoposide Plus Cisplatin Compared With Irinotecan Plus Cisplatin for First-line Treatment of Non-primary Pancreatic Metastatic and/or Unresectable Gastrointestinal Neuroendocrine Tumor G3 Type Not yet recruiting NCT03963193 Phase 2 Etoposide;Irinotecan
8 A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Recruiting NCT04234568 Phase 1 Lutetium Lu 177 Dotatate;Triapine
9 A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors Completed NCT01476592
10 A Study Evaluating The Clinical Utility Of The Health-Related Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours QUALINETS Study Completed NCT02853422
11 Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours Recruiting NCT03328065

Search NIH Clinical Center for Gastrointestinal Neuroendocrine Tumor

Genetic Tests for Gastrointestinal Neuroendocrine Tumor

Anatomical Context for Gastrointestinal Neuroendocrine Tumor

MalaCards organs/tissues related to Gastrointestinal Neuroendocrine Tumor:

40
Liver, Colon, Pancreas, Endothelial

Publications for Gastrointestinal Neuroendocrine Tumor

Articles related to Gastrointestinal Neuroendocrine Tumor:

(show all 27)
# Title Authors PMID Year
1
A Comparison of Liver-Directed Therapy and Systemic Therapy for the Treatment of Liver Metastases in Patients with Gastrointestinal Neuroendocrine Tumors: Analysis of the California Cancer Registry. 61
33358144 2021
2
A rare case of metachronous neuroendocrine tumor after a colorectal adenocarcinoma: qualitative critical review of synchronous and metachronous gastrointestinal NET. 61
33044637 2021
3
Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis. 61
33403563 2021
4
[A case of rectal submucosal tumor diagnosed with the coexistence of gastrointestinal neuroendocrine tumor G1 and adenocarcinoma following endoscopic submucosal dissection]. 61
33692259 2021
5
Comment on "Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment". 61
33065634 2020
6
Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma. 61
33041225 2020
7
Comment on "Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival with or without Liver Treatment". 61
32694442 2020
8
Improving the accuracy of gastrointestinal neuroendocrine tumor grading with deep learning. 61
32632119 2020
9
Incidence of Gastrointestinal Neuroendocrine Tumor: Case Series, Armed Forces Hospital Southern Region, Hospital-Based Tumor Board Registry. 61
33133712 2020
10
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. 61
29746336 2019
11
Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor. 61
30877189 2019
12
Gastrointestinal Neuroendocrine Tumor, Colon Adenocarcinoma, and Hyperparathyroidism: An Unorthodox Synchronism. 61
30800541 2018
13
First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. 61
29741466 2018
14
Peripancreatic paraganglioma mimics pancreatic/gastrointestinal neuroendocrine tumor on fine needle aspiration: Report of two cases and review of the literature. 61
28560856 2017
15
[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. 61
28449678 2017
16
[Diagnostic analysis for 52 cases of gastrointestinal neuroendocrine tumor]. 61
27033797 2016
17
Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. 61
26256906 2015
18
[Analysis of patients with gastrointestinal neuroendocrine tumor]. 61
24394140 2013
19
[Chylous ascites as a serious complication of the neuroendocrine tumor of ileum -  case report]. 61
24107160 2013
20
Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. 61
21431978 2011
21
[Epidemiology of gastrointestinal neuroendocrine tumor in Japan]. 61
21830613 2011
22
Molecular and functional characterization of non voltage-operated Ca entry in gastrointestinal neuroendocrine tumor cells. 61
21383891 2010
23
A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. 61
17391319 2007
24
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. 61
17340592 2007
25
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. 61
17158768 2006
26
The significance of CD44 expression in gastrointestinal neuroendocrine tumors. 61
16001632 2005
27
Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. 61
9825476 1997

Variations for Gastrointestinal Neuroendocrine Tumor

Expression for Gastrointestinal Neuroendocrine Tumor

Search GEO for disease gene expression data for Gastrointestinal Neuroendocrine Tumor.

Pathways for Gastrointestinal Neuroendocrine Tumor

Pathways related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 SSTR5 SSTR2 SSTR1 SST PKN3 MTOR
2 11.79 SSTR5 SSTR2 SSTR1 SST
3
Show member pathways
11.62 SSTR5 SSTR2 SSTR1 SST MTOR
4 11.54 MTOR ENO2 CDKN1A
5 11.47 SSTR2 SSTR1 SST HDAC9

GO Terms for Gastrointestinal Neuroendocrine Tumor

Cellular components related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 8.92 SYP SSTR5 SSTR2 SSTR1

Biological processes related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.43 SSTR5 SSTR2 SSTR1
2 negative regulation of cell proliferation GO:0008285 9.43 SSTR5 SSTR2 SSTR1 SST MEN1 CDKN1A
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.33 SSTR5 SSTR2 SSTR1
4 cellular response to glucocorticoid stimulus GO:0071385 9.32 SSTR5 SSTR2
5 somatostatin signaling pathway GO:0038170 8.8 SSTR5 SSTR2 SSTR1

Molecular functions related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.33 SSTR5 SSTR2 SSTR1
2 neuropeptide binding GO:0042923 9.13 SSTR5 SSTR2 SSTR1
3 somatostatin receptor activity GO:0004994 8.8 SSTR5 SSTR2 SSTR1

Sources for Gastrointestinal Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....